Navigation Links
New Non-Surgical Stem-Cell Procedure Relieves Degenerative Joint Disease
Date:11/8/2007

First-of-its-kind procedure from Colorado-based company

DENVER, Nov. 8 /PRNewswire/ -- Regenerative Sciences, Inc., has launched its patent-pending Regenexx(TM) procedure, which uses a patient's own stem cells to regenerate bone and cartilage -- a welcome relief for the more than 20 million Americans who suffer from painful and debilitating orthopedic conditions.

"The Regenexx procedure is different from all other treatments available today," said Chris Centeno, M.D., creator of Regenexx and an international expert and specialist in musculoskeletal, spinal and neurological injury. "Prior to Regenexx, physicians were limited in what they could offer degenerative joint patients: surgery or life with pain. Now physicians have a new tool in their tool kit."

In sanctioned clinical trials, Regenexx has been demonstrated to be safe and regenerates normal healthy tissues. A patient's stem cells are extracted with a needle from the hip, grown in culture at a Rengerative Sciences lab and then re-implanted into the patient at a doctor's office with a "needle out, needle in" approach, which substantially reduces downtime for the patient.

Unlike joint replacement or micro fracture that require weeks or months of being on crutches and pain medicines, the Regenexx procedure has no downtime. Most patients return to normal activity within 24 hours of completing the procedure.

A published clinical trial was conducted with a 46-year-old woman who had a two-year history of knee pain that began after being kicked in the shin during a martial arts class. Bone marrow was drawn from the patient, and in the next nine days, the marrow was used to grow mesenchymal stem cells, which have the ability to grow into bone, cartilage and muscle tissues. The grown stem cells initially taken from the patient were injected into her knee once a week for the next three weeks. Three months after the procedure, the patient reported that her pain had essentially disappeared. A MRI confirmed that the defect on her femur had been reduced by one-third.

Repair of the degenerated or injured area usually takes place in two to three months, and many patients feel better in one to three months.

About Regenerative Sciences

Founded in 2006, Regenerative Sciences is the Denver-based developer of Regenexx(TM), a breakthrough non-surgical option for people suffering from various orthopedic disorders. Regenexx is a patent-pending procedure that uses a person's own stem cells and blood growth factors to regenerate bone and cartilage.

The physicians at Regenerative Sciences are dedicated to providing the option of non-surgical joint repair to their patients. Headquartered in Colorado, they focus on delivering high quality treatment for people suffering from these often debilitating diseases. Visit http://www.Regenexx.com to learn more about benefits, research and the Regenexx procedure.


'/>"/>
SOURCE Regenerative Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Prominent Farmington Plastic Surgeon Uses Two New Non-Surgical Procedures to Tighten Skin and Remove Fat
2. Newly Published Study in Leading Medical Journal Further Confirms the Brava Systems Non-Surgical Breast Enhancement Effectiveness
3. UK junior doctors gaining less experience of common procedures
4. New male sling procedure helps prostate cancer survivors who suffer from urinary incontinence
5. Eligard(R) six-month formulation successfully completes European approval procedure
6. Smoking can harm the long-term effects of some oral surgery procedures
7. Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007
8. Study Shows Cosmetic Surgery on the Rise as Safety and Efficacy of Procedures Increase
9. New Device for Clearing Blocked Arteries in the Legs Receives FDA Clearance for Peripheral Use - Procedures Performed Across the US Within First 48 Hours
10. Orthopedic Development Corporations TruFUSE(R) Procedure Tops 1,750 Patients in First Year
11. Decrease in the use of radiotherapy procedures for the treatment of cancer in hospitals
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica Scruggs ... for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs surgery, ... Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, MD, ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
(Date:6/24/2016)... ... , ... June 19, 2016 is World Sickle Cell Observance Day. In an ... of holistic treatments, Serenity Recovery Center of Marne, Michigan, has issued a ... Cell Disease (SCD) is a disorder of the red blood cells, which can cause ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San ... Society and the Road To Recovery® program to drive cancer patients to and from ... adults to ensure the highest quality of life and ongoing independence. Getting to ...
(Date:6/24/2016)... Vegas, Nevada (PRWEB) , ... June 24, 2016 ... ... Las Vegas client, The Grove Investment Group (TGIG), has initiated cultivation and processing ... Grove, in Las Vegas and Pahrump, Nevada. , Puradigm is the manufacturer of ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)...   Pulmatrix, Inc ., (NASDAQ: PULM ... announced today that it was added to the Russell ... comprehensive set of U.S. and global equity indexes on ... milestone for Pulmatrix," said Chief Executive Officer Robert ... progress in developing drugs for crucial unmet medical needs, ...
(Date:6/23/2016)... BEVERLY HILLS, Calif. , June 23, 2016 ... faced the many challenges of the current process. Many of ... option because of the technical difficulties and high laboratory costs ... would have to offer it at such a high cost ... to afford it. Dr. Parsa Zadeh , ...
(Date:6/23/2016)... 2016 Capricor Therapeutics, Inc. ... biotechnology company focused on the discovery, development and ... enrollment in its ongoing randomized HOPE-Duchenne clinical trial ... of its 24-patient target. Capricor expects the trial ... of 2016, and to report top line data ...
Breaking Medicine Technology: